Biocompatibility Evaluation with ISO 10993 in Canada

1. Key takeaways

Biocompatibility evaluation in a Canadian dossier is structured around ISO 10993-1 as the framework: the evaluation endpoints are determined by the nature of contact and the duration of contact of the device, the corresponding ISO 10993 part standards are then used to complete the evaluation, and the conclusions are integrated into the risk management documentation. The ISO 10993 series is a set of consensus standards, not mandatory provisions of the Regulations. The practical consequence is that the evaluation is a reasoning exercise anchored in the risk management process rather than a fixed shopping list of tests; what the reviewer examines is whether the endpoint selection follows from the contact characterisation and whether the conclusions land in the risk file where they can be weighed against the device’s benefit-risk profile.

• ISO 10993-1 provides the framework: endpoints derive from nature of contact and duration of contact.
• Contact duration feeds both classification (Schedule 1 rules 1(3) and 2(3), 30 consecutive days) and biological evaluation.
• The ISO 10993 series is a consensus standard, not a mandatory provision of the Regulations.
• Material equivalence reasoning can reduce new testing, but the equivalence chain must be complete.
• Biocompatibility conclusions must be indexed into the risk management documentation (practical estimate on the audit linkage).

2. Legal basis

The table below lists the sources used in this article. The Medical Devices Regulations provisions were verified against Justice Laws; the classification rules cited come from Schedule 1, Part 1; the ISO 10993-1 document is a consensus standard; and the Health Canada content was verified against canada.ca, with the audit-related characterisation marked as a practical estimate.

3. Expert insights

Insight 1: contact duration influences both classification and biological evaluation, so the judgements must agree.

Schedule 1 rules 1(3) and 2(3) use the condition of remaining normally in the body, in a body cavity, or in contact with the surface of the eye for at least 30 consecutive days as a route to Class III. ISO 10993-1, for its part, uses contact duration — limited, prolonged and permanent contact — to determine which biological evaluation endpoints apply. The same physical parameter therefore operates in two separate places, and the characterisation used in one place cannot contradict the characterisation used in the other without inviting questions. If the dossier classifies the device as Class III on the basis of 30 or more consecutive days of contact, the biological evaluation must treat the contact as long-term or permanent under the standard’s own definitions; conversely, if the evaluation treats the contact as limited, the classification rationale needs to explain why the 30-day condition does not apply. Consistency here is cheap to verify at the planning stage and expensive to repair after a deficiency letter.

Insight 2: biological evaluation is a process, not a test list.

The core of ISO 10993-1 is the risk management process. The sequence runs: first characterise the nature of contact and the duration of contact; then determine the evaluation endpoints that flow from that characterisation; then plan the evaluation work that addresses those endpoints. Running the full set of biological tests on a device whose contact profile does not call for them is one of the most common and most avoidable forms of cost waste in regulatory work. A test-first approach also weakens the dossier, because raw test results without a documented rationale for endpoint selection give the reviewer nothing to judge relevance against. The process-first approach costs planning effort up front and repays it in a shorter, more defensible review.

Insight 3: material equivalence reasoning can reduce new evaluation, but the chain must be complete.

Where the device under application uses the same materials in contact with tissue as a previously marketed device, manufactured with the same processes and sterilised by the same method, equivalence reasoning can be used to leverage existing data instead of generating everything anew. The chain is only as strong as its weakest link: if the material source, an additive, a colorant, a coating or a processing step changes anywhere in the comparison, the equivalence chain is broken and the borrowed data no longer carry weight for the changed element. The practical discipline is to record the comparison item by item — material, additives, colorants, coatings, manufacturing processes, sterilisation method — and to state explicitly for each item whether it is identical, and if not, why the difference does not affect the biological conclusion.

Insight 4: the Canadian-side audit checks the linkage between biological evaluation and risk management (practical estimate).

According to industry compilation, risk management and design control are Canadian-specific MDSAP audit tasks. The biological evaluation conclusions should therefore be findable as corresponding entries in the risk management file: the hazards addressed, the evaluation evidence referenced and the residual risk conclusions drawn. Where a biological evaluation exists as a standalone report that the risk file never references, reviewers and auditors may read the evidence chain as broken. Building a two-way index — each biological evaluation section pointing to the risk entry it supports, and each relevant risk entry pointing to the evaluation section — keeps the connection visible and easy to audit.

4. Practical recommendations

• Determine the nature and duration of contact first, then fix the evaluation endpoints, then plan the evaluation work.
• Compile the material list once and completely — including additives, colorants and coatings — to avoid rework later.
• In equivalence reasoning, verify materials, processes and sterilisation item by item; if any one differs, the equivalence cannot be invoked.
• Build a two-way index between the biological evaluation conclusions and the risk management documentation.
• When citing the ISO 10993 series, identify it as a consensus standard.

5. Verification checklist

• □ The nature and duration of contact have been determined.
• □ The evaluation endpoint list follows from the contact determination.
• □ The material list, including additives and coatings, is complete.
• □ Equivalence reasoning has verified materials, processes and sterilisation item by item.
• □ A two-way index between biological evaluation conclusions and the risk management file exists.
• □ Cited standards are identified as consensus standards.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com